Trade

with

Dynavax Technologies Corp
(NASDAQ: DVAX)
AdChoices
1.51
+0.03
+2.03%
After Hours :
1.51
0.00
0.00%

Open

1.50

Previous Close

1.48

Volume (Avg)

3.98M (1.49M)

Day's Range

1.48-1.53

52Wk Range

1.10-2.14

Market Cap.

396.95M

Dividend Rate ( Yield )

-

Beta

2.56

Shares Outstanding

262.88M

P/E Ratio (EPS)

-

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
Industry Biotechnology
Highlights
Analyst Recommendation: Not Available
    • Revenue

    • 11.25M

    • Net Income

    • -66.72M

    • Market Cap.

    • 396.95M

    • Enterprise Value

    • -

    • Net Profit Margin %

    • -615.40

    • PEG (Price/Earnings Growth) Ratio

    • -

    • Beta

    • 2.56

    • Forward P/E

    • -

    • Price/Sales

    • 28.99

    • Price/Book Value

    • 2.63

    • Price/Cash flow

    • -5.88

      • EBITDA

      • -65.39M

      • Return on Capital %

      • -54.65

      • Return on Equity %

      • -64.43

      • Return on Assets %

      • -54.65

      • Book Value/Share

      • 0.57

      • Shares Outstanding

      • 262.88M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • -

      • Dividend Declaration Date

      • -

      Analyst Recommendation
      -
      Not Available
        • 1 Year Price Target

        • -

        • Credit Rating

        • -

        • Analysts

        • 0

        • EPS Estimate

        • -

        • Cashflow Estimate

        • -

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • -10.10

          • 40.73

          • Net Income

            YTD/YTD (last year)

          • -

          • 17.04

          • Net Income

            Q/Q (last year)

          • -

          • 98.90

          • Sales (Revenue)

            5-Year Annual Average

          • -21.23

          • 63.43

          • Net Income

            5-Year Annual Average

          • -

          • 10.65

          • Dividends

            5-Year Annual Average

          • -

          • 15.81

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • 100.00

            • 82.75

            • Pre-Tax Margin

            • -546.66

            • 39.38

            • Net Profit Margin

            • -615.40

            • 31.33

            • Average Gross Margin

              5-Year Annual Average

            • 100.00

            • 82.99

            • Average Pre-Tax Margin

              5-Year Annual Average

            • -

            • 33.42

            • Average Net Profit Margin

              5-Year Annual Average

            • -385.70

            • 199.05B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • -

              • 0.76

              • Current Ratio

              • 7.96

              • 2.92

              • Quick Ratio

              • 7.71

              • 2.35

              • Interest Coverage

              • 1,142.49

              • 38.02

              • Leverage Ratio

              • 1.15

              • 2.21

              • Book Value/Share

              • 0.57

              • 4.76

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • -4.49

                • 238.10

                • P/E Ratio 5-Year High

                • -16.64

                • 634.30

                • P/E Ratio 5-Year Low

                • -3.05

                • 124.82

                • Price/Sales Ratio

                • 27.62

                • 8.94

                • Price/Book Value

                • 2.51

                • 8.12

                • Price/Cash Flow Ratio

                • -5.88

                • 47.85

                • Key Metrics

                • Company

                • Industry

                  • Return on Equity %

                    (5-Year Average)

                  • -64.43

                    (-136.40)

                  • 37.63

                    (27.20)

                  • Return on Assets %

                    (5-Year Average)

                  • -54.65

                    (-53.50)

                  • 17.22

                    (13.81)

                  • Return on Capital %

                    (5-Year Average)

                  • -64.49

                    (-94.80)

                  • 21.78

                    (17.31)

                  • Income/Employee

                  • -

                  • 117.08k

                  • Inventory Turnover

                  • -

                  • 1.48

                  • Asset Turnover

                  • 0.09

                  • 0.55

                  Current Historical
                  Financials
                  • Income Statement
                  • Balance Sheet
                  • Cash Flow
                  Operating Income
                  -66.49M
                  Operating Margin
                  -590.95
                  Total Equity
                  -
                  Retained Earnings
                  -
                  Free Cashflow
                  -
                  Price/Cashflow
                  -5.88
                  Ownership

                  Institutional Ownership

                  65.43%

                  Top 10 Institutions

                  46.50%

                  Mutual Fund Ownership

                  38.34%

                  Float

                  84.65%

                  5% / Insider Ownership

                  0.73%

                  Corporate insiders or major stockholders reporting trading activity in the stock.

                  Top Mutual Fund Owners

                  Top Institutional Owners

                  Mutual Fund Name

                  Institution Name

                  • Mutual Fund Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • AST Federated Aggressive Growth

                  •  

                    17,993,000

                  • 0.00

                  • 6.84

                  • Federated Kaufmann Small Cap Fund

                  •  

                    16,122,000

                  • -3.46

                  • 6.13

                  • Polar Capital Healthcare Opps

                  •  

                    10,483,854

                  • 0.00

                  • 3.99

                  • Vanguard Total Stock Mkt Idx

                  •  

                    5,726,102

                  • 28.93

                  • 2.18

                  • Franklin Biotechnology Discovery

                  •  

                    5,418,400

                  • 137.36

                  • 2.06

                  • Putnam Voyager Fund

                  •  

                    5,170,700

                  • 11.11

                  • 1.97

                  • SPDR® S&P Biotech ETF

                  •  

                    5,082,252

                  • 0.60

                  • 2.00

                  • iShares Russell 2000 (AU)

                  •  

                    4,109,547

                  • -1.01

                  • 1.62

                  • Harbor Small Cap Growth Fund

                  •  

                    4,076,178

                  • -3.09

                  • 1.55

                  • Vanguard Extended Market Index Fund

                  •  

                    3,242,077

                  • 0.23

                  • 1.23

                  • Institution Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Federated Global Inv Mgmt Corp

                  •  

                    34,115,000

                  • +89.48%

                  • 12.98

                  • RA Capital Management, LLC

                  •  

                    14,036,590

                  • -21.51%

                  • 5.34

                  • Westfield Capital Management Company, LP

                  •  

                    13,668,111

                  • -0.15%

                  • 5.20

                  • Polar Capital LLP

                  •  

                    10,946,861

                  • +1.85%

                  • 4.16

                  • State Street Corp

                  •  

                    10,146,462

                  • -26.03%

                  • 3.86

                  • Vanguard Group, Inc.

                  •  

                    9,101,496

                  • -0.36%

                  • 3.46

                  • BlackRock Fund Advisors

                  •  

                    8,258,043

                  • +2.96%

                  • 3.14

                  • Franklin Advisers, Inc.

                  •  

                    7,879,100

                  • 0.00%

                  • 3.00

                  • Broadfin Capital, LLC

                  •  

                    7,660,100

                  • 0.00%

                  • 2.91

                  • Putnam Investment Management,LLC

                  •  

                    6,449,368

                  • +11.58%

                  • 2.45

                  Company Profile

                  Sector

                  Healthcare

                  Industry

                  Biotechnology

                  Type

                  Slow Growth

                  Style

                  Small Core

                  Dynavax Technologies Corp was incorporated in California in August 1996 under the name Double Helix Corporation, and it changed its name to Dynavax Technologies Corporation in September 1996. The Company reincorporated in Delaware in...more 2000. The Company is a clinical-stage biopharmaceutical company. It discovers and develops novel products to prevent and treat infectious and inflammatory diseases. The Company’s product candidate is HEPLISAVTM, a Phase 3 investigational adult hepatitis B vaccine. Its pipeline of product candidates includes: HEPLISAV, its autoimmune program partnered with GlaxoSmithKline, and its therapy for asthma partnered with AstraZeneca AB. Its product candidates are based on the use of immunostimulatory and immunoregulatory sequences. HEPLISAV is an investigational adult hepatitis...more B vaccine. In Phase 3 trials, HEPLISAV demonstrated higher and earlier protection with fewer doses than currently licensed vaccines. The Company has worldwide commercial rights to HEPLISAV. HEPLISAV combines its first generation 1018 ISS with hepatitis B surface antigen manufactured in its facility in Düsseldorf, Germany. The Company competes with pharmaceutical companies, biotechnology companies, academic institutions and research organizations, in developing therapies to prevent or treat infectious diseases and inflammatory and autoimmune diseases. Any product candidate it develops is subject to extensive regulation by federal, state and local governmental authorities in the United States, including the FDA and foreign regulatory agencies.lessless

                  Key People

                  Eddie Gray

                  CEO/Director

                  Dr. Arnold L. Oronsky,PhD

                  Chairman of the Board/Director

                  Michael S. Ostrach

                  CFO/General Counsel/Other Executive Officer/Secretary/Vice President

                  David L. Johnson,C.P.A.

                  Vice President/Chief Accounting Officer

                  Mr. Robert Janssen

                  Chief Medical Officer/Vice President, Divisional

                  • Dynavax Technologies Corp

                  • 2929 Seventh Street

                  • Berkeley, CA 94710-2753

                  • USA.Map

                  • Phone: +1 510 848-5100

                  • Fax: +1 510 848-1327

                  • dynavax.com

                  Incorporated

                  1996

                  Employees

                  151

                  Send Feedback

                  We appreciate your input!

                  • I'm having trouble signing into my Microsoft account

                  • I’m having problems with the services stripe (Mail, Facebook, etc.)

                  • There is an issue with my weather information

                  • I see an error in the content

                  • Other

                  Please give an overall site rating: